Literature DB >> 24373631

Relaxin as novel strategy in the management of atrial fibrillation: potential roles and future perspectives.

Zhiqiang Zhao1, Chee Yuan Ng2, Tong Liu1, Hongmin Li1, Guangping Li3.   

Abstract

Entities:  

Keywords:  Atrial fibrillation; Fibrosis; Inflammation; Oxidative stress; Relaxin

Mesh：

Substances：

Year:  2013        PMID： 24373631     DOI： 10.1016/j.ijcard.2013.11.103

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN： 0167-5273            Impact factor:   4.164


× No keyword cloud information.
  4 in total

Review 1.  Heart Disease and Relaxin: New Actions for an Old Hormone.

Authors:  Teja Devarakonda; Fadi N Salloum
Journal:  Trends Endocrinol Metab       Date:  2018-03-08       Impact factor: 12.015

2.  Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial.

Authors:  Gerasimos Filippatos; Dimitrios Farmakis; Marco Metra; Gad Cotter; Beth A Davison; G Michael Felker; Barry H Greenberg; Tsushung A Hua; Peter S Pang; Piotr Ponikowski; Min Qian; Thomas A Severin; Adriaan A Voors; John R Teerlink
Journal:  Clin Res Cardiol       Date:  2017-02-01       Impact factor: 5.460

3.  Effects of febuxostat on atrial remodeling in a rabbit model of atrial fibrillation induced by rapid atrial pacing.

Authors:  Yong-Yan Fan; Feng Xu; Chao Zhu; Wen-Kun Cheng; Jian Li; Zhao-Liang Shan; Yang Li; Yu-Tang Wang
Journal:  J Geriatr Cardiol       Date:  2019-07       Impact factor: 3.327

4.  Relaxin Inhibits Ventricular Arrhythmia and Asystole in Rats With Pulmonary Arterial Hypertension.

Authors:  Brian Martin; Rebecca R Vanderpool; Brian L Henry; Joshua B Palma; Beth Gabris; Yen-Chun Lai; Jian Hu; Stevan P Tofovic; Rajiv P Reddy; Ana L Mora; Mark T Gladwin; Guillermo Romero; Guy Salama
Journal:  Front Cardiovasc Med       Date:  2021-07-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.